Literature DB >> 35915215

A quality improvement initiative to reduce necrotizing enterocolitis in high-risk neonates.

Stephanie C Mavis1, Maria C Gallup2, Mikael Meyer2, Megan M Misgen3, Laura A Schram3, Danielle L Herzog4, Brandi N Smith5, Virginia S Schuning3, Raymond C Stetson3, Jennifer L Fang3.   

Abstract

OBJECTIVE: Prompted by an acute increase in necrotizing enterocolitis (NEC) rates, we aimed to decrease the rate of stage 2 or greater NEC in infants born at <1500 grams or <30 weeks gestational age from 19.5% to less than 9.7% (a 50% reduction) within 18 months, without adversely affecting central line-associated bloodstream infection (CLABSI) rates. STUDY
DESIGN: We utilized Define, Measure, Analyze, Improve, and Control (DMAIC) as our improvement model. Informed by our key driver diagram and root cause analyses, six Plan-Do-Study-Act cycles were completed.
RESULTS: 147 infants in the QI initiative had a median gestational age of 28.1 weeks and a median birthweight of 1070 grams. NEC rates decreased from the QI baseline of 19.5% to 6% (p = 0.03). Oral care administration increased, and maximal gavage tube dwell time decreased.
CONCLUSION: NEC rates decreased during this QI initiative through a combination of multidisciplinary interventions aimed at reducing dysbiosis.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 35915215     DOI: 10.1038/s41372-022-01476-5

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   3.225


  1 in total

1.  Enhancement of immune response mediated by oropharyngeal colostrum administration in preterm neonates.

Authors:  Jorge Moreno-Fernandez; Belén Sánchez-Martínez; Laura Serrano-López; Estefanía Martín-Álvarez; Javier Diaz-Castro; Manuela Peña-Caballero; Francisca Martín-Peregrina; Mercedes Alonso-Moya; José Maldonado-Lozano; Julio J Ochoa; Jose A Hurtado-Suazo
Journal:  Pediatr Allergy Immunol       Date:  2018-12-13       Impact factor: 6.377

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.